Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Infant Bacterial Therapeutics AB's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. The number is 0, which means that Infant Bacterial Therapeutics AB has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Infant Bacterial Therapeutics AB's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Infant Bacterial Therapeutics AB Net Issuance of Preferred Stock Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Net Issuance of Preferred Stock Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Infant Bacterial Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Infant Bacterial Therapeutics AB Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Infant Bacterial Therapeutics AB Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines